CONSORCIO MAR PARC DE SALUT DE BARCELONA

Their core work

Hospital del Mar Research Institute (IMIM) is a biomedical research center embedded in the Barcelona public hospital system, conducting clinical and translational research across psychiatry, oncology, and population health screening. They specialize in turning large-scale patient data and genomic information into actionable clinical tools — from predicting lithium response in bipolar disorder to risk-stratified breast cancer screening. Their work bridges bioinformatics and clinical practice, with a strong track record in multi-country clinical validation studies and drug development pipelines, including a first-in-human study for cognitive improvement in Down syndrome.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), HMRIB-CERCA focused heavily on bioinformatics infrastructure and computational methods — building tools to connect genotype data to clinical phenotypes across oncology and psychiatry. From 2020 onward, the focus shifted decisively toward applied clinical validation: population screening programs (liver fibrosis, breast cancer), occupational mental health interventions, and clinical drug development (ICOD). The trajectory is clear — from building analytical platforms to deploying them in real-world clinical and public health settings.

Moving from data-driven research tools toward direct clinical application, with growing ambition in drug development and large-scale population health interventions.

How they like to work

HMRIB-CERCA primarily operates as a clinical research partner within large European consortia (162 unique partners across 26 countries), contributing patient cohorts, clinical expertise, and data analysis capabilities. They have coordinated twice — once for a bioinformatics platform (MedBioinformatics) and once for a high-stakes drug development project (ICOD, their largest grant), suggesting they step into leadership when the topic closely aligns with their core clinical strengths. Their broad partner network and consistent participant role make them a reliable, well-connected consortium member rather than a dominant consortium builder.

With 162 unique consortium partners across 26 countries, HMRIB-CERCA has one of the broader collaboration networks for a hospital-based research institute, spanning Western and Southern Europe extensively with connections into Scandinavia and Eastern Europe.

What sets them apart

HMRIB-CERCA sits at the intersection of hospital-based clinical research and advanced bioinformatics — a combination that lets them both generate patient data and analyze it computationally, which many partners in a consortium cannot do alone. Their psychiatric and neurological focus (bipolar disorder, Down syndrome cognition, prenatal brain development, workplace mental health) is unusually deep for a general hospital research institute. For consortium builders, they offer the rare ability to contribute both clinical trial sites and data science capacity within a single partner.

Highlights from their portfolio

• ICOD
  Their largest project (EUR 1.4M) and a coordinator role — a first-in-human clinical trial targeting cognitive deficits in Down syndrome, signaling serious ambition in rare disease drug development.
• MedBioinformatics
  Coordinated a EUR 891K bioinformatics platform connecting oncology and CNS disorder data — the foundational project that established their computational medicine credentials.
• MyPeBS
  Part of a major international randomized study on personalized breast cancer screening running until 2027, demonstrating long-term commitment to population health innovation.